Last reviewed 2026-05-31 · How we verify

MTX, MVD, VIA

Samsung Medical Center · Phase 2 active Small molecule ✓ Verified May 2026

MTX, MVD, VIA is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development.

MTX (Methotrexate) is a small molecule used in chemotherapy for conditions such as CNS Lymphoma. MVD and VIA are also interventions studied in clinical trials for CNS Lymphoma, but their specific mechanisms and indications are not specified in the provided facts.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MTX, MVD, VIA
Sponsor	Samsung Medical Center
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MTX, MVD, VIA CI brief — competitive landscape report
MTX, MVD, VIA updates RSS · CI watch RSS
Samsung Medical Center portfolio CI

Frequently asked questions about MTX, MVD, VIA

What is MTX, MVD, VIA?

MTX, MVD, VIA is a Small molecule drug developed by Samsung Medical Center.

Who makes MTX, MVD, VIA?

MTX, MVD, VIA is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

What development phase is MTX, MVD, VIA in?

MTX, MVD, VIA is in Phase 2.

Manufacturer: Samsung Medical Center — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing